iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Cipla-led arm recalls one lot of Vigabatrin owing to seal intergrity issue

11 Dec 2023 , 11:41 AM

Cipla, a pharmaceutical company, announced on Sunday that its subsidiary is voluntarily recalling one lot of medicine in the United States owing to seal integrity problems.

According to a regulatory filing, InvaGen Pharmaceuticals Inc, USA, is voluntarily recalling one lot of Vigabatrin for Oral Solution, USP (500 mg) at the consumer level due to seal integrity concerns that allow powder leaking from the bag.

An improper pouch seal may cause powder mix to leak outside the pouch, resulting in a reduced amount of medicine inside the pack compared to the label claim and possibly underdosing, it noted.

It noted that in certain individuals, there is a significant possibility that incorrect dose would result in a major adverse impact, such as intoxication or breakthrough seizures, necessitating medical intervention.

A decline in phenytoin blood levels might result in life-threatening seizures for a tiny proportion of individuals who have severe or frequent breakthrough seizures, according to the study.

The medicine is used as supplementary therapy in patients two years of age and older who have reacted effectively to numerous other therapies for refractory complex partial seizures.

According to Cipla, the drug is packed in foil pouches, each containing 500mg of Vigabatrin, and a shelf pack has 50 foil-sealed pouches.

For feedback and suggestions, write to us at editorial@iifl.com

 

Related Tags

  • Cipla
  • Cipla Drug
  • Cipla Drug Recall
  • Cipla news
  • Cipla Updates
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.